Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment.

Trial Profile

Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Infliximab
  • Indications Behcet's syndrome
  • Focus Therapeutic Use
  • Acronyms BIO BEHCET'S
  • Most Recent Events

    • 20 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top